Christiane Juhls

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.

Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.

Journal: Antimicrobial agents and chemotherapy

Published: February 06, 2015

Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent.

Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent.

Journal: BMC veterinary research

Published: December 05, 2014

Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.

Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.

Journal: Gene therapy

Published: November 03, 2014

Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.

Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.

Journal: BMC veterinary research

Published: October 15, 2014

Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.

Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.

Journal: BMC veterinary research

Published: October 13, 2014

Influences of age and sex on leukocytes of healthy horses and their ex vivo cytokine release.

Influences of age and sex on leukocytes of healthy horses and their ex vivo cytokine release.

Journal: Veterinary immunology and immunopathology

Published: July 30, 2014

Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.

Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.

Journal: Science translational medicine

Published: May 03, 2014

Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine.

Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine.

Journal: PloS one

Published: February 14, 2014

Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: studies on formulation, biodistribution and vector clearance.

Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: studies on formulation, biodistribution and vector clearance.

Journal: Vaccine

Published: December 19, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026